ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > fidelity?

<< Previous

Bullboard Posts

Next >>

Comment by Mole101on Sep 23, 2021 8:49pm

103 Views

Post# 33912313

RE:RE:fidelity?

I'm going to guess that Fidelity is the MM of the moment, Mackey Research was the MM earlier in the year ..someone has to keep the action off buying/ selling and likely they unload through Anon..,

Mole101 wrote:

From: To:

36,510,365 ($7,439,953) PMN.TO shares exchanged hands from Wed Jun 23 2021 to Thu Sep 23 2021.

House Bought Sold Net

House 022

Fidelity

Bought $1,638,079

Volume 8,095,000

Average $0.202

Sold $12,846

Volume 62,073

Average $0.207

Net $1,625,233

Volume 8,032,927

M101 wrote: Who is the buyer through Fidelity? I think it's been mentioned here before but I don't remember, part of the Boston group? Do they plan to hold?